Abstract
This paper discusses the basic principles of drug/P-glycoprotein (P-gp) interaction, focusing on the methodology and design of positron emission tomography (PET) studies investigating P-gp function. The requirements of a good PET P-gp radiotracer are also evaluated. (R)-[11C]verapamil is used as an example, as this drug is the most common tracer for P-gp studies, but [11C]loperamide, [11C]desmethyl-loperamide and other compounds are also mentioned. The article also discusses the various study designs that can be used for PET drug disposition studies, such as administration of the inhibitor before or after the radiolabeled drug (tracer) and the use of bolus injections or infusions. Concepts such as the unbound partition coefficient (Kp,uu) and the volume of distribution of unbound drug in brain (Vu,brain), which are not easily measured directly with PET, can be used to describe the impact of protein binding and non-specific binding on drug distribution in brain tissue. It is concluded that new imaging probes will be required if the role of PET in studies of the interactions of drugs with efflux transporters is to expand.
Keywords: P-glycoprotein, PET, study design, pharmacokinetics, blood-brain barrier, active transport, efflux pumps, drug interactions
Current Topics in Medicinal Chemistry
Title: Using PET Studies of P-gp Function to Elucidate Mechanisms Underlying the Disposition of Drugs
Volume: 10 Issue: 17
Author(s): Stina Syvanen and Margareta Hammarlund-Udenaes
Affiliation:
Keywords: P-glycoprotein, PET, study design, pharmacokinetics, blood-brain barrier, active transport, efflux pumps, drug interactions
Abstract: This paper discusses the basic principles of drug/P-glycoprotein (P-gp) interaction, focusing on the methodology and design of positron emission tomography (PET) studies investigating P-gp function. The requirements of a good PET P-gp radiotracer are also evaluated. (R)-[11C]verapamil is used as an example, as this drug is the most common tracer for P-gp studies, but [11C]loperamide, [11C]desmethyl-loperamide and other compounds are also mentioned. The article also discusses the various study designs that can be used for PET drug disposition studies, such as administration of the inhibitor before or after the radiolabeled drug (tracer) and the use of bolus injections or infusions. Concepts such as the unbound partition coefficient (Kp,uu) and the volume of distribution of unbound drug in brain (Vu,brain), which are not easily measured directly with PET, can be used to describe the impact of protein binding and non-specific binding on drug distribution in brain tissue. It is concluded that new imaging probes will be required if the role of PET in studies of the interactions of drugs with efflux transporters is to expand.
Export Options
About this article
Cite this article as:
Syvanen Stina and Hammarlund-Udenaes Margareta, Using PET Studies of P-gp Function to Elucidate Mechanisms Underlying the Disposition of Drugs, Current Topics in Medicinal Chemistry 2010; 10 (17) . https://dx.doi.org/10.2174/156802610792927997
DOI https://dx.doi.org/10.2174/156802610792927997 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
In Search of Novel AMPA Potentiators
Recent Patents on CNS Drug Discovery (Discontinued) One Pot Synthesis, Characterization, DFT Studies and AIM Analyses of Ethyl-1-aryl-1H-tetrazole-5-carboxylate
Letters in Organic Chemistry Personalized Medicine Using Cutting Edge Technologies for Genetic Epilepsies
Current Neuropharmacology Different Food Odors Control Brain Connectivity in Impulsive Children
CNS & Neurological Disorders - Drug Targets Lessons Learned from Muscle Fatigue: Implications for Treatment of Patients with Hyperkalemic Periodic Paralysis
Recent Patents on Biotechnology Nicotine, Lung and Cancer
Anti-Cancer Agents in Medicinal Chemistry Mouse Models of Familial Hemiplegic Migraine for Studying Migraine Pathophysiology
Current Neuropharmacology The Pathophysiological Basis of Carotid Baroreceptor Stimulation for the Treatment of Resistant Hypertension
Current Vascular Pharmacology HCN Channels Modulators: The Need for Selectivity
Current Topics in Medicinal Chemistry Anticonvulsant Effect of the Essential Oil and Methanolic Extracts of <i>Zataria multiflora</i> Boiss
Central Nervous System Agents in Medicinal Chemistry Cytopathological Mechanisms in Mitochondrial Disease
Current Chemical Biology A Review of Pharmacokinetic Parameters of Metabolites and Prodrugs
Drug Metabolism Letters Conantokins Inhibitors of Ion Flow through the N-Methyl-D-Aspartate Receptor Channels
Current Drug Targets QSAR Studies for the Pharmacological Inhibition of Glycogen Synthase Kinase-3
Medicinal Chemistry The Structure and Functions of P-Glycoprotein
Current Medicinal Chemistry Commonalities in Biological Pathways, Genetics, and Cellular Mechanism between Alzheimer Disease and Other Neurodegenerative Diseases: An In Silico-Updated Overview
Current Alzheimer Research Antiepileptics for Post-Traumatic Seizure Prophylaxis after Traumatic Brain Injury
Current Pharmaceutical Design Recombinant Expression, Functional Characterization of Two Scorpion Venom Toxins with Three Disulfide Bridges from the Chinese Scorpion Buthus martensii Karsch
Protein & Peptide Letters Recent Developments of the PET Imaging Agents for Metabotropic Glutamate Receptor Subtype 5
Current Topics in Medicinal Chemistry REM sleep and its Loss-Associated Epigenetic Regulation with Reference to Noradrenaline in Particular
Current Neuropharmacology